clinical trial · NCT07653685
A Clinical Study of TQB2930 Injection and Chemotherapy With or Without Bevacizumab in the Treatment of Advanced Colorectal Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.·phase2·not yet recruiting·n = 71
Colorectal CancerTQB2930 injection + Oxaliplatin injection + Capecitabine tablets + Bevacizumab injectionTQB2930 injection + Oxaliplatin injection + Capecitabine tablets
brief summary
To assess the safety and preliminary efficacy of TQB2930 and chemotherapy with or without bevacizumab in subjects with HER2-positive unresectable locally advanced or metastatic colorectal cancer (CRC).
started
Jul 1, 2026
primary completion
Jun 1, 2027
completion
Dec 1, 2028
last updated
Jun 17, 2026
official title
A Phase Ib/II Clinical Study to Evaluate the Efficacy and Safety of TQB2930 Injection and Chemotherapy With or Without Bevacizumab in Subjects With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Unresectable Locally Advanced or Metastatic Colorectal Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol